glp-1 and no gallbladder Medications Health: What You Should Know GLP-1 Gallbladder Risk: What Clinicians

BMJ 342 , d1165 (2011)

Clinical trials show semaglutide achieves an average of 15% total body weight loss over 68 weeks

On average, 33% of Hispanic adults are obese, while 41% of Black adults are considered obese

You should contact your GP to discuss stopping GLP-1 treatment if you are experiencing: Persistent or severe side effects that significantly impact your quality of life, such as ongoing nausea, vomiting, diarrhoea, or abdominal pain that does not improve with time or dose adjustment

For obesity, AACE and Obesity Society guidelines endorse using GLP-1 RAs when BMI criteria are met and lifestyle measures need augmentation, especially if there are weight-related comorbidities

But they have different approved uses